OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

OptimizeRx’s upgraded NLAB unifies HCP and DTC audience building, adding ZIP-9 level Micro-Neighborhood Targeting for privacy-safe precision.

Rhea-AI Summary

OptimizeRx (OPRX) has expanded its AI-powered Natural Language Audience Builder (NLAB) so media planners can create both claims-grade healthcare professional (HCP) and privacy-safe direct-to-consumer (DTC) audiences in a single, plain-language workflow.

The upgrade integrates the company’s Micro-Neighborhood® Targeting (MNT) audiences, turning NLAB into a platform-agnostic, no-code audience tool for life sciences media planning. From one patient audience description, users can generate NPI lists and consumer segments in minutes and activate them across programmatic and major media channels. New DTC-focused features include decile-based, interactive views of audience quality and reach, plus instant media channel propensity and demographic insights for audience-specific media mix planning.

Market Context

Before publication, OPRX's prior daily close was $7.29, with a 1.53% 24-hour gain; the NLAB expansio...

Analysis

Before publication, OPRX's prior daily close was $7.29, with a 1.53% 24-hour gain; the NLAB expansion added HCP and DTC audience functionality without disclosed financial terms.

Key Figures

Audience data granularity: ZIP-9 level

Audience data granularity

ZIP-9 level

Micro-Neighborhood Targeting audiences

Key Terms

hcp, deterministic, programmatic, zip-9

4 terms

hcp medical

"claims-grade HCP audiences and privacy-safe direct-to-consumer"

An HCP (healthcare professional) is a licensed medical practitioner—such as a doctor, nurse, pharmacist or clinician—who diagnoses, treats and advises patients. For investors, HCPs are important because their prescribing choices and treatment recommendations directly affect product sales and market uptake, acting like gatekeepers whose preferences and acceptance can determine a therapy’s commercial success and regulatory exposure.

deterministic technical

"create deterministic HCP and consumer audiences faster"

Deterministic describes a system, model, or process that produces the same result every time given the same starting conditions and inputs, with no role for chance. For investors, deterministic forecasts or rules act like a recipe: they make outcomes predictable and reproducible, which helps with planning and risk controls, but they can miss real-world randomness and unexpected events that affect returns.

programmatic technical

"activate those audiences across programmatic and other major media channels"

"Programmatic" describes the automated process of buying and selling financial assets or advertising space using computer systems and algorithms. It allows transactions to happen quickly and efficiently, often without human intervention, similar to how vending machines dispense snacks automatically. For investors, programmatic methods can lead to faster decision-making and more precise targeting of opportunities, potentially enhancing overall investment performance.

zip-9 technical

"MNT audiences combine de-identified clinical and consumer data at the ZIP-9 level"

A ZIP-9 is the nine-digit U.S. postal code that combines the standard five-digit ZIP with an additional four digits to pinpoint a more specific delivery area, like a city block, group of apartments, or a single large building. For investors and companies, using a ZIP-9 improves the accuracy of mail delivery for regulatory notices, shareholder communications, and legal documents—think of it as moving from a city map to a detailed street-address view.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points has expanded its patent-pending, AI-powered Natural Language Audience Builder (NLAB) tool to allow media planners and buyers to build both claims-grade HCP audiences and privacy-safe direct-to-consumer (DTC) audiences in the same workflow, from a shared plain-language prompt.

This expansion adds OptimizeRx’s Micro-Neighborhood^® Targeting (MNT) audiences to NLAB, transforming NLAB from an HCP audience-building solution into a platform-agnostic, no-code audience tool for comprehensive life sciences media planning. From a single patient audience description, marketers can create and optimize both NPI lists and consumer segments in minutes, and then seamlessly activate those audiences across programmatic and other major media channels.

Alongside the addition of MNT audiences, the expansion also adds new optimization and media planning functionality specific to the DTC landscape, including:

• Decile-based, interactive breakdowns of audience quality (AQ) and reach, so planners can adjust audience precision and scale in real-time to reflect different campaign goals
• Instant generation of media channel propensities and audience demographics for NLAB-created audiences or natural language audience prompts, so planners can create media mix strategies optimized for their specific brand populations

MNT audiences combine de-identified clinical and consumer data at the ZIP-9 level to create custom, privacy-safe, deterministic audiences with hyperlocal precision, providing a scalable alternative to modeled or probabilistic targeting. As a result of the NLAB integration, non-healthcare-native platforms or marketing agencies can now embed validated healthcare audience intelligence without investing in proprietary data or enterprise data licensing agreements.

“Life sciences marketers need audiences grounded in real healthcare behavior relevant to their brand, not generic segments or modelled proxies,” said Mike Rousselle, Chief AI Officer, OptimizeRx. “By bringing MNT into NLAB, we’re not only giving media planners a more streamlined way to build, refine, and activate consumer audiences, but also enabling the precision that can lead to higher marketing engagement and impact.”

“The more complexity NLAB removes for DSPs, agencies, and their life sciences clients, the easier it becomes to put sophisticated audience intelligence to work,” said Stephen Silvestro, CEO, OptimizeRx. “By making both HCP and consumer audiences available on demand, we can reduce friction for our partners and expand the role OptimizeRx plays across their planning and activation strategies.”

To learn more about NLAB and OptimizeRx’s MNT audience technology, visit www.optimizerx.com/technology.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "allow", "build”, “transforming”, "can", "activate", "embed", "validate", "helps" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the ability of DSPs and agency planners to create deterministic HCP and consumer audiences faster, marketers’ ability to seamlessly activate audiences across programmatic and other major media channels, the ability of non-healthcare-native platforms or marketing agencies to embed validated healthcare audience intelligence without investing in proprietary data or enterprise data licensing agreements, the addition of audiences enabling precision leading to higher marketing engagement and impact, and the ability to reduce friction for the Company’s partners by making HCP and consumer audience available on demand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Jennifer Dinkel, SVP Marketing
jdinkel@optimizerx.com

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com

Press Inquiries
Matter Communications
optimizerx@matternow.com

Partnership Inquires
Louis Trivento, SVP Strategic Partnerships
ltrivento@optimizerx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are Micro-Neighborhood® Targeting (MNT) audiences in OptimizeRx’s platform?

MNT audiences combine de-identified clinical and consumer data at the ZIP-9 level to create custom, privacy-safe, deterministic audiences with hyperlocal precision. They provide a scalable alternative to modeled or probabilistic targeting and allow healthcare-relevant audience segments to be defined without exposing identifiable patient information.

How does the NLAB expansion help non-healthcare-native platforms and agencies?

The integration of MNT into NLAB allows non-healthcare-native platforms and marketing agencies to embed validated healthcare audience intelligence without investing in proprietary data assets or enterprise data licensing agreements. NLAB’s no-code, natural-language interface lets these users access claims-grade HCP and DTC audiences directly within their existing planning workflows.

What new DTC media planning capabilities were added to NLAB?

NLAB now offers decile-based, interactive breakdowns of audience quality (AQ) and reach so planners can adjust precision and scale in real time for different campaign goals. It also instantly generates media channel propensities and audience demographics for NLAB-created audiences or natural language prompts, supporting audience-specific media mix strategy development.

How does OptimizeRx describe the benefit of unifying HCP and consumer audiences in NLAB?

The company states that making both HCP and consumer audiences available on demand reduces friction for DSPs, agencies, and life sciences clients and broadens the role OptimizeRx can play across planning and activation strategies, while enabling audience precision that may support higher marketing engagement and impact.